Pharmion - Best Pharma Stocks of 2007

Company: Pharmion
Starting stock price: $26.7
Ending stock price: $62.68
Percent Change: 135%

Details: Pharmion acquires, develops and commercializes hematology and oncology products. In November 2007, Celgene bought Pharmion for $2.9 billion--11 times Pharmion's annual revenue and a 46 percent premium for its shares. Pharmion sells Vidaza and Thalomid and is working on a late-stage therapy for small-cell lung cancer and a mid-stage oncology drug MGCD0103.

More News:
Celgene goes global with $2.9B Pharmion buyout. Report
Pharmion nets cancer therapy in Cabrellis buyout. Report
Pharmion signs $270M licensing deal for GPC's satraplatin. Report

Pharmion - Best Pharma Stocks of 2007

Suggested Articles

Perrigo is treading water in its specialty drugs reinvention plan. Could a merger with another struggling drugmaker—à la Pfizer and Mylan—be the cure?

AveXis' ex-CSO is "prepared to assert his rights and defend his conduct accordingly," a statement from a lawyer who recently represented Elon…

Hikma says it has picked up some pipeline products and nasal and sublingual spray equipment from Insys Therapeutics' bankruptcy.